Effectiveness and Costs of Molecular Screening and Treatment for Bacterial Vaginosis to Prevent Preterm Birth
Authors: Bretelle Florence , Loubière Sandrine , Desbriere Raoul , Loundou Anderson , Blanc Julie , Heckenroth Hélène , Schmitz Thomas , Benachi Alexandra , Haddad Bassam , Mauviel Franck , Danoy Xavier , Mares Pierre , Chenni Nawal , Ménard Jean-Pierre , Cocallemen Jean-François , Slim Nadia , Sénat Marie Victoire , Chauleur Céline , Bohec Caroline , Kayem Gilles , Trastour Cynthia , Bongain André , Rozenberg Patrick , Serazin Valerie , Fenollar Florence ,   Groupe de Recherche en Obstetrique et Gynécologie (GROG) Investigators, Ego Anne , Deneux-tharaux Catherine , Carbonne Bruno , Leray Camille , Subtil Damien , D'Ercole Claude , Gallot Denis , Vayssiere Christophe , Perrotin Franck , Goffinet Francois , Berveiller Paul , Sentilhes Loic , Debarge Veronique , Salomon Laurent , Garabedian Charles , Haumonté Jean Baptiste , Quibel Thibaud , Fuchs Florent , Baumstarck Karine , Auquier Pascal , Fortanier Cécile 
Published: July 2023

ImportanceBacterial vaginosis (BV) is a well-known risk factor for preterm birth. Molecular diagnosis of BV is now available. Its impact in the screening and treatment of BV during pregnancy on preterm births has not been evaluated to date.ObjectiveTo evaluate the clinical and economic effects of point-of-care quantitative real-time polymerase chain reaction screen and treat for BV in low-risk pregnant women on preterm birth.Design, Setting, and ParticipantsThe AuTop trial was a prospective, multicenter, parallel, individually randomized, open-label, superiority trial conducted in 19 French perinatal centers between March 9, 2015, and December 18, 2017. Low-risk pregnant women before 20 weeks’ gestation without previous preterm births or late miscarriages were enrolled. Data were analyzed from October 2021 to November 2022.InterventionsParticipants were randomized 1:1 to BV screen and treat using self-collected vaginal swabs (n = 3333) or usual care (n = 3338). BV was defined as Atopobium vaginae (Fannyhessea vaginae) load of 108 copies/mL or greater and/or Gardnerella vaginalis load of 109 copies/mL or greater, using point-of-care quantitative real-time polymerase chain reaction assays. The control group received usual care with no screening of BV.Main Outcomes and MeasuresOverall rate of preterm birth before 37 weeks’ gestation and total costs were calculated in both groups. Secondary outcomes were related to treatment success as well as maternal and neonate health. Post hoc subgroup analyses were conducted.ResultsAmong 6671 randomized women (mean [SD] age, 30.6 [5.0] years; mean [SD] gestational age, 15.5 [2.8] weeks), the intention-to-treat analysis of the primary clinical and economic outcomes showed no evidence of a reduction in the rate of preterm birth and total costs with the screen and treat strategy compared with usual care. The rate of preterm birth was 3.8% (127 of 3333) in the screen and treat group and 4.6% (153 of 3338) in the control group (risk ratio [RR], 0.83; 95% CI, 0.66-1.05; P = .12). On average, the cost of the intervention was €203.6 (US $218.0) per participant, and the total average cost was €3344.3 (US $3580.5) in the screen and treat group vs €3272.9 (US $3504.1) in the control group, with no significant differences being observed. In the subgroup of nulliparous women (n = 3438), screen and treat was significantly more effective than usual care (RR, 0.62; 95% CI, 0.45-0.84; P for interaction = .003), whereas no statistical difference was found in multiparous (RR, 1.30; 95% CI, 0.90-1.87).Conclusion and RelevanceIn this clinical trial of pregnant women at low risk of preterm birth, molecular screening and treatment for BV based on A vaginae (F vaginae) and/or G vaginalis quantification did not significantly reduce preterm birth rates. Post hoc analysis suggests a benefit of screen and treat in low-risk nulliparous women, warranting further evaluation in this group.Trial RegistrationClinicalTrials.gov Identifier: NCT02288832